Entourage Health (ENTG) Q2 2024 earnings summary

Executive summary

• Q2 2024 was marked by heightened competition, pricing pressures, and oversupply, leading to a more consolidated cannabis market.

• Total revenue for Q2 2024 was $12.2 million, reflecting ongoing growth in bulk sales and new product launches across key provinces.

• Despite a challenging quarter, year-to-date performance and targets remain on track, with consistent results compared to the same period last year.

• Strategic focus has shifted to distribution expansion, product innovation, and operational efficiency to drive sustainable growth.

• Restructuring initiatives led to a year-over-year decline in SG&A expenses, supporting improved operational efficiency.

Financial highlights

• Q2 2024 total revenue decreased by CAD 1.1 million (9%) to CAD 12.2 million year-over-year.

• Net revenue for Q2 2024 was $9.3 million, down 9% year-over-year; six-month net revenue was $28.6 million, stable versus prior year.

• Gross profit before changes in fair value was $0.7 million (8% margin), down from $2.1 million (21%) in Q2 2023; cost of goods sold increased due to higher biomass costs.

• EBITDA for Q2 2024 increased 8% to $3.2 million; six-month EBITDA rose 159% to $4.3 million year-over-year.

• SG&A expenses dropped by CAD 2.1 million (31%) year-over-year, reflecting restructuring and cost-saving initiatives.

Outlook and guidance

• Management remains focused on cash preservation, operational efficiency, and adapting to market conditions.

• Strategic focus on expanding distribution, launching targeted products, and forming partnerships to scale operations.

• The company is committed to margin amplification, revenue growth, and product innovation for 2024 and beyond.